WARREN, N.J., Nov. 6, 2014 /PRNewswire/ -- Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today reported its financial results for the three months ended September 30, 2014.
Financial Results
Revenue for the quarter ended September 30, 2014 were $1.5 million compared to $556,000 for the third quarter of 2013 and $1.4 million for the second quarter of 2014. The increase in third quarter revenue year-on-year resulted from an increase in the number of Atlas® instruments placed with commercial customers and increased commercial utilization of the instruments. As of September 30, 2014, the Company had 36 instruments placed with customers under commercial agreements compared to 23 instruments as of September 30, 2013 and 36 instruments as of June 30, 2014.
“Although our commercialization efforts did not result in additional instrument placements in the quarter, we continue to make good progress with our targeted strategic accounts,” said Paul Thomas, Roka Bioscience President and Chief Executive Officer. “Despite the challenges associated with the launch of innovative technologies such as our Atlas Detection Assays, we remain focused on increasing revenue from our existing customer relationships while continuing to expand our strategic customer base.”
Total operating expenses for the third quarter were $9.9 million compared to $7.8 million for the same period in 2013. Net loss for the third quarter was $9.1 million, or a loss of $(0.64) per share, compared with $9.4 million, or a loss of $(17.00) per share, for the same period in 2013.
As of September 30, 2014, the Company had $62.8 million in cash, which included the proceeds received by the Company in connection with its IPO in July. During the third quarter, the Company made $10.5 million in cash payments to reduce the royalty rate paid to Gen-Probe pursuant to its license agreement.
Conference Call
Roka Bioscience will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and answer questions. To listen to the conference call live, go to http://rokabio.investorroom.com/ or dial 1-888-347-1331 for domestic callers and 1-412-902-4277 for international callers. A replay of the call will be available commencing two hours after the completion of the call through November 19, 2014 by dialing 1-877-344-7529 domestic and 1-412-317-0088 international, passcode 10055107. An online archive of the conference call will also be available at http://rokabio.investorroom.com/.
About Roka Bioscience
Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our “sample-in, result-out” Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.
To read full press release, please click here.
Help employers find you! Check out all the jobs and post your resume.
